$3440 | Single User
$5910 | Enterprise License

Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcyla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer and Lymphoma) - Global Opportunity Analysis and Industry Forecast 2017-2023.
[Report Updated: 01-09-2017]

Published by Allied Market Research: 01 Sep 2017 | 123319 | In Stock
Related Topics: Antibodies , Biotherapeutics , Breast Cancer , Cancer , Lymphoma , Novartis , Pfizer , Roche

Introduction

The antibody drug conjugates market was valued at ,387 million in 2016, and is estimated to reach ,198 million by 2023, registering a CAGR of 12.9% from 2017 to 2023. Antibody drug conjugates (ADC’s) are promising and effective anticancer medications employed for efficient treatment of cancer patients. ADC’s are biopharmaceutical drugs prepared by integrating two clinical approaches viz cell killing HPAPI (powerful pharmaceutical ingredient) and monoclonal antibody specificity. This combination approach enables elimination of cancer infected cells without harming healthy cells in patient’s body.

Increase in global prevalence of cancer and demand for quality & cost-effective cancer medications drives the global ADCs market. In addition, extensive R&D for cancer medication and approval of new cancer drugs is expected to boost the market growth during the forecast period. However, high cost involved in R&D of cancer medication and stringent government regulations impedes the growth of antibody drug conjugates market.

The report segments the market based on drugs, mechanism of action, application, and region. Based on drugs, the market is bifurcated into Adcetris and Kadcyla. Based on mechanism of action, it is divided into CD30 antibodies and HER2 antibodies. Based on application, the market is classified into breast cancer, lymphoma, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS

The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.

It offers a quantitative analysis from 2017 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.

Extensive analysis by product elucidates the various types of ADC’s used for diverse cancer therapeutic procedures

Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.

Key players are profiled and their strategies are analyzed thoroughly, which helps understand the competitive outlook of the global ADCs market.

KEY PLAYERS PROFILED

F. Hoffman-La Roche Ltd.

Novartis AG

Takeda Pharmaceutical Company Limited

Pfizer, Inc.

Seattle Genetics Inc.

Genentech Inc.

Immunogen Inc.

Immunomedics, Inc.

Progenics Pharmaceuticals Inc.

Bayer AG

KEY MARKET SEGMENTS

BY DRUGS

Adcetris

Kadcyla

BY MECHANISM OF ACTION

CD30 Antibodies

HER2 Antibodies

BY APPLICATION

Breast Cancer

Lymphoma

By Region

North America

U.S.

Canada

Mexico

Europe

France

Germany

UK

Italy

Spain

The Netherlands

Norway

Russia

Sweden

Switzerland

Rest of Europe

Asia-Pacific

Japan

China

India

Australia

South Korea

New Zealand

Taiwan

Thailand

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Chile

Columbia

Egypt

Iran

Israel

Turkey

Venezuela

Rest of LAMEA

The other players of the anesthesia market include (companies not profiled in the report):

Agensys, Inc.

Concortis Biotherapeutics

Sanofi S.A.

Celldex Therapeutics Inc.

Synthon Holding B.V.

Table of Contents
for Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcyla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer and Lymphoma) - Global Opportunity Analysis and Industry Forecast 2017-2023. [Report Updated: 01-09-2017]

  • CHAPTER 1 INTRODUCTION

    1.1. REPORT DESCRIPTION

    1.2. KEY BENEFITS

    1.3. KEY MARKET SEGMENTS

    1.4. RESEARCH METHODOLOGY

    1.4.1. Secondary research

    1.4.2. Primary research

    1.4.3. Analyst tools & models

    CHAPTER 2 EXECUTIVE SUMMARY

    2.1. CXO PERSPECTIVE

    CHAPTER 3 MARKET OVERVIEW

    3.1. MARKET DEFINITION AND SCOPE

    3.2. KEY FINDINGS

    3.2.1. Top investment pockets

    3.2.2. Top winning strategies

    3.3. TOP PLAYER POSITIONING

    3.4. PATENTS ANALYSIS

    3.4.1. Patent analysis by year

    3.4.2. Patent analysis by region

    3.5. PORTERS FIVE FORCES ANALYSIS

    3.5. MARKET DYNAMICS

    3.5.1. Drivers

    3.5.2. Restraints

    3.5.3. Opportunities

    CHAPTER 4 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS

    4.1. OVERVIEW

    4.1.1. Market size & forecast

    4.2. ADCETRIS

    4.2.1. Key market trends

    4.2.2. Growth factors and opportunities

    4.2.3. Market size & forecast

    4.3. KADCYLA

    4.3.1. Key market trends

    4.3.2. Growth factors and opportunities

    4.3.3. Market size & forecast

    CHAPTER 5 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION

    5.1. OVERVIEW

    5.1.1. Market size & forecast

    5.2. CD30 ANTIBODIES

    5.2.1. Market size & forecast

    5.3. HER2 ANTIBODIES

    5.3.1. Market size & forecast

    CHAPTER 6 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION

    6.1. OVERVIEW

    6.1.1. Market size & forecast

    6.2. BREAST CANCER

    6.2.1. Market size & forecast

    6.3. LYMPHOMA

    6.3.1. Market size & forecast

    CHAPTER 7 GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY GEOGRAPHY

    7.1. OVERVIEW

    7.2. NORTH AMERICA

    7.2.1. Key market trends

    7.2.2. Key growth factors and opportunities

    7.2.3. Market size & forecast

    7.2.3.1. U.S. market size and forecast

    7.2.3.2. Canada market size and forecast

    7.2.3.3. Mexico market size and forecast

    7.3. EUROPE

    7.3.1. Key market trends

    7.3.2. Key growth factors and opportunities

    7.3.3. Market size & forecast

    7.3.3.1. Germany market size and forecast

    7.3.3.2. France market size and forecast

    7.3.3.3. UK market size and forecast

    7.3.3.4. Italy market size and forecast

    7.3.3.5. Spain market size and forecast

    7.3.3.5. Rest of Europe market size and forecast

    7.4. ASIA-PACIFIC

    7.4.1. Key market trends

    7.4.2. Key growth factors and opportunities

    7.4.3. Market size & forecast

    7.4.3.1. Japan market size and forecast

    7.4.3.2. China market size and forecast

    7.4.3.3. Australia market size and forecast

    7.4.3.4. India market size and forecast

    7.4.3.5. South Korea market size and forecast

    7.4.3.5. Taiwan market size and forecast

    7.4.3.7. Rest of Asia-Pacific market size and forecast

    7.5. LAMEA

    7.5.1. Key market trends

    7.5.2. Key growth factors and opportunities

    7.5.3. Market size & forecast

    7.5.3.1. Brazil market size and forecast

    7.5.3.2. Turkey market size and forecast

    7.5.3.3. Saudi Arabia market size and forecast

    7.5.3.4. South Africa market size and forecast

    7.5.3.5. Rest of LAMEA market size and forecast

    CHAPTER 8 COMPANY PROFILES

    8.1. PFIZER, INC.

    8.1.1. Operating business segments

    8.1.2. Business performance

    8.2. CELLDEX THERAPEUTICS INC.

    8.2.1. Operating business segments

    8.2.2. Business performance

    8.2.3. Key strategic moves and developments

    8.3. SEATTLE GENETICS INC.

    8.3.1. Operating business segments

    8.3.2. Business performance

    8.3.3. Key strategic moves and developments

    8.4. GENENTECH INC.

    8.4.1. Operating business segments

    8.4.2. Business performance

    8.4.3. Key strategic moves and developments

    8.5. IMMUNOGEN INC.

    8.5.1. Operating business segments

    8.5.2. Business performance

    8.5.3. Key strategic moves and developments

    8.5. SANOFI S.A.

    8.5.1. Operating business segments

    8.5.2. Business performance

    8.5.3. Key strategic moves and developments

    8.7. IMMUNOMEDICS, INC.

    8.7.1. Operating business segments

    8.7.2. Business performance

    8.7.3. Key strategic moves and developments

    8.8. PROGENICS PHARMACEUTICALS INC.

    8.8.1. Operating business segments

    8.8.2. Business performance

    8.8.3. Key strategic moves and developments

    8.8. BAYER HEALTHCARE PHARMACEUTICALS

    8.8.1. Operating business segments

    8.8.2. Business performance

    8.8.3. Key strategic moves and developments

    8.10. SYNTHON HOLDING B.V.

    8.10.1. Operating business segments

    8.10.2. Business performance

    8.10.3. Key strategic moves and developments

List Of Tables
in Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcyla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer and Lymphoma) - Global Opportunity Analysis and Industry Forecast 2017-2023. [Report Updated: 01-09-2017]

TABLE 1. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 ($MILLION)

TABLE 2. ADCETRIS ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)

TABLE 3. KADCYLA ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)

TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 ($MILLION)

TABLE 5. CD30 ANTIBODIES ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)

TABLE 6. HER2 ANTIBODIES ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)

TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION, 2016-2023 ($MILLION)

TABLE 8. BREAST CANCER ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)

TABLE 9. LYMPHOMA ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2016-2023 ($MILLION)

TABLE 10. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 11. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 ($MILLION)

TABLE 12. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 ($MILLION)

TABLE 13. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION 2016-2023 ($MILLION)

TABLE 14. EUROPE ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 15. EUROPE ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 ($MILLION)

TABLE 16. EUROPE ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 ($MILLION)

TABLE 17. EUROPE ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION 2016-2023 ($MILLION)

TABLE 18. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 19. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 ($MILLION)

TABLE 20. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 ($MILLION)

TABLE 21. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION 2016-2023 ($MILLION)

TABLE 22. LAMEA ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 23. LAMEA ANTIBODY DRUG CONJUGATES MARKET, BY DRUGS, 2016-2023 ($MILLION)

TABLE 24. LAMEA ANTIBODY DRUG CONJUGATES MARKET, BY MECHANISM OF ACTION, 2016-2023 ($MILLION)

TABLE 25. LAMEA ANTIBODY DRUG CONJUGATES MARKET, BY APPLICATION 2016-2023 ($MILLION)

TABLE 26. PFIZER, INC.: COMPANY SNAPSHOT

TABLE 27. PFIZER, INC.: PRODUCT PORTFOLIO

TABLE 28. CELLDEX THERAPEUTICS INC: COMPANY SNAPSHOT

TABLE 29. CELLDEX THERAPEUTICS INC: PRODUCT PORTFOLIO

TABLE 30. SEATTLE GENETICS INC: COMPANY SNAPSHOT

TABLE 31. SEATTLE GENETICS INC: PRODUCT PORTFOLIO

TABLE 32. GENENTECH INC: COMPANY SNAPSHOT

TABLE 33. GENENTECH INC: PRODUCT PORTFOLIO

TABLE 34. IMMUNOGEN INC: COMPANY SNAPSHOT

TABLE 35. IMMUNOGEN INC: PRODUCT PORTFOLIO

TABLE 36. SANOFI S.A.: COMPANY SNAPSHOT

TABLE 37. SANOFI S.A.: PRODUCT PORTFOLIO

TABLE 38. IMMUNOMEDICS, INC: COMPANY SNAPSHOT

TABLE 39. IMMUNOMEDICS, INC: PRODUCT PORTFOLIO

TABLE 40. PROGENICS PHARMACEUTICALS INC.: COMPANY SNAPSHOT

TABLE 41. PROGENICS PHARMACEUTICALS INC.: PRODUCT PORTFOLIO

TABLE 42. BAYER HEALTHCARE PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 43. BAYER HEALTHCARE PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 44. SYNTHON HOLDING B.V.: COMPANY SNAPSHOT

TABLE 45. SYNTHON HOLDING B.V.: PRODUCT PORTFOLIO

List Of Figures, Charts and Diagrams
in Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcyla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer and Lymphoma) - Global Opportunity Analysis and Industry Forecast 2017-2023. [Report Updated: 01-09-2017]

FIGURE 1. ANTIBODY DRUG CONJUGATES MARKET: MARKET SEGMENATION

FIGURE 2. TOP INVESTMENT POCKETS: GLOBAL DNA SEQUENCING MARKET, BY APPLICATION

FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)

FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE

FIGURE 5. TOP WINNING STRATEGIES: NATURE AND COMPANY

FIGURE 5. TOP PLAYER POSITIONING: GLOBAL ANTIBODY DRUG CONJUGATES MARKET

FIGURE 7. PATENT ANALYSIS BY YEAR

FIGURE 8. PATENT ANALYSIS BY REGION

FIGURE 9. BARGAINING POWER OF BUYERS

FIGURE 10. BARGAINING POWER OF SUPPLIERS

FIGURE 11. THREAT OF NEW ENTRANTS

FIGURE 12. THREAT OF SUBSTITUTION

FIGURE 13. COMPETITIVE RIVALRY

FIGURE 14. ANTIBODY DRUG CONJUGATES MARKET: DRUGS SEGMENATION

FIGURE 15. ANTIBODY DRUG CONJUGATES MARKET: MECHANISM OF ACTION SEGMENATION

FIGURE 16. ANTIBODY DRUG CONJUGATES MARKET: BY APPLICATION SEGMENATION

FIGURE 17. U.S. ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 18. CANADA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 19. MEXICO ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 20. GERMANY ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 21. FRANCE ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 22. UK ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 23. ITALY ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 24. SPAIN ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 25. REST OF EUROPE ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 26. JAPAN ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 27. CHINA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 28. AUSTRALIA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 29. INDIA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 30. SOUTH KOREA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 31. TAIWAN ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 32. REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 33. BRAZIL ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 34. TURKEY ANTIBODY DRUG CONJUGATES MARKET, 2016-20223 ($MILLION)

FIGURE 35. SAUDI ARABIA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 36. SOUTH AFRICA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

FIGURE 37. REST OF LAMEA ANTIBODY DRUG CONJUGATES MARKET, 2016-2023 ($MILLION)

Additional Details

Publisher

Allied Market Research

Publisher Information

Reference

123319 | LI 171467

Number of Pages

152

Report Format

PDF

Allied Market Research Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials
The Global Antibody Partnering Terms and Agreements 2010 to 2016 report provides comprehensive under...
01 Nov 2016 by Current Partnering USD $2,995 More Info
Anti-CD22 Immunotherapeutics in: October 2016 R&D and Business Tracker for Antibody-Drug Conjugates
Anti-CD22 Immunotherapeutics in:October 2016 R&D and Business Tracker for Antibody-Drug Conjuga...
01 Nov 2016 by La Merie USD $225 More Info
Anti-Her2 Antibody-Drug Conjugates in: September 2016 R&D and Business Tracker for Antibody-Drug Conjugates
Anti-Her2 Antibody-Drug Conjugates in:September 2016 R&D and Business Tracker for Antibody-Drug ...
01 Oct 2016 by La Merie USD $225 More Info
R&D and Business Tracker for Antibody-Drug Conjugates
R&D and Business Tracker for Antibody-Drug Conjugates - a monthly update service This informa...
01 Sep 2016 by La Merie USD $1,350 More Info
4-Antibody AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary4-Antibody AG (4-Antibody), a subsidiary of Agenus, Inc. is a biopharmaceutical company that ...
29 Jul 2016 by Global Data USD $250 More Info
4-Antibody AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary4-Antibody AG (4-Antibody), a subsidiary of Agenus, Inc. is a biopharmaceutical company that ...
05 May 2016 by Global Data USD $250 More Info
Antibody Target, Technology & Pipeline Database: 1-Year Subscription
Antibody Target, Technology & Pipeline Database: 1-Year SubscriptionTherapeutic monoclonal anti...
01 Apr 2016 by La Merie USD $1,600 More Info
Antibody Target, Technology & Pipeline Database: 1-Year Subscription
Antibody Target, Technology & Pipeline Database: 1-Year SubscriptionTherapeutic monoclonal anti...
01 Apr 2016 by La Merie USD $1,600 More Info
4-Antibody AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary4-Antibody AG (4-Antibody), a subsidiary of Agenus, Inc. is a biopharmaceutical company that ...
08 Mar 2016 by Global Data USD $250 More Info
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeho...
30 Nov 2015 by La Merie USD $500 More Info

This report is published by Allied Market Research

Download Free Report Summary PDF

Antibody Drug Conjugates Market by Drugs (Adcetris and Kadcyla), Mechanism of Action (CD30 Antibodies and HER2 Antibodies), Application (Breast Cancer and Lymphoma) - Global Opportunity Analysis and Industry Forecast 2017-2023. [Report Updated: 01-09-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...